丹参粉针剂对四氯化碳致大鼠慢性肝纤维化的保护作用

Protection of rats from CCl_4-induced hepatic fibrosis with Danshen powder for injection

目的:探讨丹参粉针剂对四氯化碳(CCl_4)致大鼠慢性肝纤维化的保护作用。方法:SD大鼠随机分为正常组、模型组、阳性对照组(葡醛内酯注射液26．5 mg·kg^(-1))和丹参粉针剂低、中、高剂量组(100,250, 500 mg·kg^(-1)),除正常组外的其余各组动物先在饮水中加入350 mg·L^(-1)的苯巴比妥诱导2周,然后腹腔注射CCl_4 0．04 mL·kg^(-1)建立慢性肝纤维化模型,每周1次,共注射8周。于注射CCl_4第5周时,各组分别腹腔注射生理氯化钠溶液或相应剂量的药物,在给药2,4,6周后测定血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)活性和前胶原肽(PIIIP)、层黏连蛋白(LN)、透明质酸(HA)的含量。结果:丹参粉针剂低、中、高剂量组和阳性对照组大鼠血清中ALT,AST活性和PIIIP,LN,HA含量均比模型组明显降低(P＜0．01～P＜0．05)。结论:丹参粉针剂对CCl_4致大鼠慢性肝纤维化具有保护作用。

Objective： To assess the protective effect of Danshen powder for injection on CC14-induced hepatic fibrosis in rats. Methods ： SD rats were supplemented with phenobarbital （350 mg· L^-1 ） for 2 weeks and then abdominally injected with CC14（0.04 mL·kg^-1） once per week for 8 weeks to induce rat hepatic fibrosis. The rats with hepatic fibrosis were randomly assigned to one of model or treat- ment groups. The rats was treated with either Danshen powder for injection （ 100, 250 or 500 mg·kg^-1 ） or glucurolactone injection 26.5 mg· kg^-1（ positive control） per day for 6 weeks in week 5 post CC14. The effectiveness was evaluated based on the levels of aspartate transaminase （AST）, alanine transaminase （ALT）, hepatic hyaluronic acid （HA） , laminin （LN） , type III procollagen （PIIIP） before injection and in weeks 2, 4 and 6 post injections. Results： Danshen powder for injection significantly reduced the serum levels of AST, ALT, HA, LN and PIIIP of rats （P 〈0.01-0.05）. Conclusion： Danshen powder for injection protects rats from CCl4-induced liver fibrosis.